本人作为江苏亚虹医药科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《江苏亚虹医药科技股 份有限公司章程》（以下简称"《公司章程》"）、《上市公司独立董事管理办法》的 有关规定，本着对公司及全体股东负责的态度，以关注和维护全体股东特别是中 小股东利益为宗旨，2023 年度，本人诚信、勤勉地履行独立董事的职责，对各项 议案进行认真审议，积极参与公司决策，为公司治理结构的完善和规范运作起到 了积极作用。现将具体工作情况汇报如下： 江苏亚虹医药科技股份有限公司 2023 年度独立董事述职报告 一、独立董事的基本情况 （一）独立董事人员情况 公司第一届董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数三分 之一以上，符合相关法律法规及公司制度的规定。 公司于 2023 年 12 月 28 日完成换届选举工作，第二届董事会由 9 名董事组 成，其中独立董事 3 名，占董事会人数三分之一以上，符合相关法律法规及公司 制度的规定。 （二）个人工作履历、专业背景以及兼职情况 黄彬，1967 年生，中国国籍，无境外永久居留权。黄彬先生于北京师范大学 取得学士学 ...

江苏亚虹医药科技股份有限公司 董事会审计委员会 2023 年度履职情况报告 根据《上市公司治理准则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》等法律法规以及《江苏亚虹医药科技股份有限公司章程》 （以下简称"《公司章程》"）等规章制度的要求，我们作为江苏亚虹医药科技股 份有限公司（以下简称"公司"）董事会审计委员会成员，现就 2023 年度履职情 况作如下报告： 一、董事会审计委员会基本情况 公司第一届董事会审计委员会由独立董事张炳辉先生、独立董事秦扬文先生、 董事江新明先生共 3 名委员组成，其中主任委员会由具有专业会计资格的独立董 事张炳辉先生担任。 报告期内，公司第一届董事会任期届满，公司于 2023 年 12 月 28 日召开 2023 年第一次临时股东大会完成换届选举，并同日召开第二届董事会第一次会议，审 议通过《关于选举公司第二届董事会各专门委员会委员及召集人的议案》，选举 产生第二届董事会审计委员会。公司第二届董事会审计委员会由独立董事张炳辉 先生、独立董事王文宁女士和董事江新明先生共 3 名委员组成，其中主任委员由 具有专业会计资格的独立董事张炳辉先生担任。独立董事人数 ...

一、独立董事独立性自查情况 江苏亚虹医药科技股份有限公司董事会 2023 年度关于独立董事独立性评估的专项意见 经核查，公司独立董事黄彬、张炳辉、王文宁的兼职、任职情况以及其 签署的独立性自查情况报告，上述人员除在公司担任独立董事及董事会专 门委员会委员外，不存在在公司任职以及在公司主要股东单位任职的情形， 与公司以及主要股东之间不存在利害关系、重大业务往来或其他可能妨碍 其独立性的关系。因此，董事会认为公司独立董事符合《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》中对独立董事独立性的相关要求。 江苏亚虹医药科技股份有限公司董事会 2024 年 4 月 17 日 江苏亚虹医药科技股份有限公司（以下简称"公司"）现有独立董事 3 人，为黄彬、张炳辉、王文宁。根据《上市公司独立董事管理办法》第六条 的规定，公司独立董事对自身的独立性情况进行了自查，并将自查情况提交 了董事会。自查结果显示，公司独立董事均符合《上市公司独立董事管理办 法》第六条的独立性要求，与公司及主要股东、实际控制人不存在直接或者 间接利害关系，或者其他可能影响其进行独立客观判断关系的情形，能够 ...

Stock Incentive Plan - The company implemented a restricted stock incentive plan in 2022, granting a total of 9,790,800 shares, accounting for 1.72% of the total shares, to 151 employees, representing 38.32% of the total workforce[4] - In 2023, the company granted an additional 1,925,000 restricted shares to 18 employees at a price of 6.79 RMB per share, with 4.22 million shares remaining unallocated and automatically expired[5][8] - The total share-based payment expense recognized in the reporting period for the 2022 restricted stock incentive plan was 16,400,970.53 RMB[9] - Key executives and core technical personnel, including the Chairman and CEO, were granted restricted shares, with the Chairman receiving 1.3 million shares and other executives receiving between 22,500 to 130,000 shares each[12] Financial Performance - Revenue for 2023 reached 13,753,343.12 yuan, a significant increase compared to 2022's 26,095.32 yuan[18] - Net profit attributable to shareholders in 2023 was -400,434,603.65 yuan, a decrease from -246,549,785.26 yuan in 2022[18] - Operating cash flow for 2023 was -398,186,688.82 yuan, down from -241,960,907.88 yuan in 2022[18] - Total assets at the end of 2023 were 2,632,270,467.20 yuan, a decrease of 8.41% compared to 2022[18] - Basic earnings per share for 2023 were -0.70 yuan, compared to -0.43 yuan in 2022[19] - Weighted average return on equity for 2023 was -15.52%, down from -8.52% in 2022[19] - Revenue in Q4 2023 was 10,757,271.87 yuan, the highest among all quarters[23] - Net profit attributable to shareholders in Q4 2023 was -132,390,991.55 yuan, the lowest among all quarters[23] - Government subsidies in 2023 amounted to 6,953,033.26 yuan, an increase from 5,929,193.05 yuan in 2022[24] - Non-recurring gains and losses in 2023 totaled 31,788,811.50 yuan, a decrease from 63,493,965.12 yuan in 2022[27] Asset and Investment Changes - The company's trading financial assets decreased by 1,108,968,660.80 RMB, from 1,703,276,190.24 RMB to 594,307,529.44 RMB, impacting the current profit by 23,932,781.55 RMB[31] - The company's other current assets increased by 14,544,364.54 RMB, impacting the current profit by 1,459,111.24 RMB[31] - The company's other equity instrument investments increased by 805,424.10 RMB, from 15,336,049.20 RMB to 16,141,473.30 RMB[31] Product Development and Clinical Trials - The company has 2 marketed products and 13 products in clinical and preclinical development, including 6 in clinical development, with APL-1702 and APL-1202 being global first-in-class drugs[38] - The company's APL-1202, in combination with tislelizumab, showed a significant increase in histological response rate in a Phase II clinical trial for muscle-invasive bladder cancer[35] - The company is preparing to submit an NDA for APL-1702 to the NMPA and is discussing a Phase III clinical trial plan with the FDA for the US market[35] - APL-1202 combined with chemotherapy for recurrent NMIBC did not meet the primary endpoint in the ACCRUE study, leading to the termination of further development in this indication[75] - In the ASCERTAIN study, APL-1202 monotherapy showed similar non-recurrence rates compared to chemotherapy in untreated intermediate-risk NMIBC patients, with 8 out of 21 patients completing over 1 year of treatment[78] - APL-1202 combined with Tislelizumab in the ANTICIPATE study showed a pCR rate of 39% vs 21% for Tislelizumab alone, with promising efficacy signals in MIBC patients[79] - The ANTICIPATE study is expected to release top-line Phase II data in Q3 2024, with plans to prioritize clinical development in China for advanced bladder cancer[80] - APL-1501, a second-generation product of APL-1202, is undergoing Phase I trials in Australia, aiming to improve efficacy and reduce side effects with better pharmacokinetic properties[83] - The company plans to initiate clinical studies in the US for APL-1501 combined with immune checkpoint inhibitors for BCG-unresponsive NMIBC patients, with discussions with FDA planned for 2024[83] - APL-1202 combined with immune checkpoint inhibitors is expected to improve the efficacy of advanced bladder cancer patients, with a current single-agent ORR of only around 25%[84] - APL-1706, a diagnostic imaging agent for bladder cancer, has been approved in over 30 countries and completed Phase III clinical trials in China, showing a 43.3% additional detection rate of bladder cancer lesions compared to standard white light cystoscopy[85] - APL-1706's Phase III clinical trial demonstrated an additional detection rate of ≥1 CIS lesion in 9.6% of subjects, with real-world studies showing a 7.1% additional detection rate[85] - APL-1706's New Drug Application (NDA) was accepted by the National Medical Products Administration in November 2023, with expected approval by June 2025[88] - APL-1702 showed a significant improvement in response rate by 89.4% compared to placebo (41.1% vs. 21.7%, p = 0.0001) in its Phase III clinical trial[90] - APL-1702 demonstrated a 41.4% improvement in HPV clearance rate in the mITT population (28.0% vs. 19.8%) and a 103.9% improvement for high-risk HPV16 and/or HPV18 (31.4% vs. 15.4%)[90] - APL-1702's Phase III clinical trial results were selected for oral presentations at the 2024 EUROGIN and SGO conferences[91] - APL-1702 Phase III clinical trial enrolled 402 patients from multiple countries including China, Germany, and the Netherlands[120] - The trial evaluates the efficacy and safety of APL-1702 for HSIL, with primary endpoint being response rate at 6 months post-treatment[120] - Response rate and HPV16+/HPV18+ clearance rate were compared between APL-1702 and placebo groups[121] - APL-1702 is expected to redefine the treatment goals for cervical precancerous lesions, shifting focus from one-time surgical outcomes to long-term disease management, aiming to balance treatment risks and benefits while avoiding or delaying invasive surgeries[123] - The company plans to submit a pre-submission communication to the European Medicines Agency (EMA) for APL-1702 in Q3 2024 and aims to discuss registration clinical trial designs with the US FDA for the North American market in 2024[123] - APL-1401, a novel oral drug for ulcerative colitis (UC), is undergoing Ib phase clinical trials in 12 centers across China and the US, with completion expected in 2025[124] - APL-2301, a novel antibacterial drug for Acinetobacter baumannii infections, has been approved for Phase I clinical trials in Australia, focusing on safety, tolerability, and pharmacokinetics[128] - The company is developing APL-2302, a USP1 inhibitor, which has shown strong tumor-killing effects in preclinical studies and is planned for clinical trial applications in 2024[129][130][131] - APLD-2304, a portable blue-light bladder soft scope, is being developed to improve specificity and reduce false positives in bladder cancer diagnosis, with ongoing exploration of overseas commercialization opportunities[132][135] - AT-014, a high-selective growth factor receptor inhibitor, is being optimized using AI technology for treating bladder cancer and other advanced solid tumors[136] - AT-017, an epigenetic-related small molecule oral drug, is being developed for urogenital system tumors, with ongoing lead compound optimization using TAIDD platform[137] - AT-018 is a self-developed small molecule oral drug targeting cell cycle-related pathways, specifically for treating female-related cancers such as breast cancer, ovarian cancer, and endometrial cancer. The company utilizes the TAIDD platform for multi-conformation simulation and AI for compound optimization[138] - AT-020 is a next-generation ADC drug targeting new tumor antigens, with potential to address unmet clinical needs in bladder and breast cancers. Existing ADC drugs like Enfortumab Vedotin show an ORR of 50%-60% in advanced urothelial cancer, indicating significant room for improvement[139] - AT-021 is an ADC drug aimed at enhancing anti-tumor immunity by combining self-developed immune-boosting small molecules with targeted antibodies. It aims to improve efficacy and reduce side effects of current immunotherapies like CTLA-4 and PD-1 antibodies[140] - APL-1702, a photodynamic medical device combination product, is being developed for cervical high-grade squamous intraepithelial lesions, with plans to submit a Phase III clinical trial application to the FDA[146] - APL-1202, targeting MetAP2, is in development for untreated intermediate-risk NMIBC and as a neoadjuvant therapy for MIBC in combination with tislelizumab[146] - APL-1501, a second-generation APL-1202, is being developed for urological tumors, with clinical trials planned in Australia[146] - AT-014 and AT-020 are in development for urological tumors and various solid tumors, respectively, leveraging the TAIDD and ADC platforms[146] - APL-2302, targeting USP1, is being developed for ovarian and breast cancers, with global rights[146] Commercialization and Market Access - The company's oncology division has rapidly built a nearly 200-person commercialization team, aiming for over 100 million RMB in sales and internal break-even in 2024[39] - The company's HCCM platform has over 8,000 users, with more than 85% of registered doctors being from relevant fields, and nearly 1,500 interactions in the breast cancer field[40] - The company achieved sales of 9.2892 million yuan for its oncology products, including Dypate and Ouyoubi, by the end of the reporting period[63] - The company's oncology products, Dypate and Ouyoubi, achieved coverage in 80% of target cities by Q4 2023 and 100% by Q1 2024[68] - Dypate achieved sales in over 70% of target key hospitals within six months of launch, while Ouyoubi connected with major customers and benefited over 1,000 patients within three months of launch[68] - The company's market access team achieved 90% provincial bidding and dual-channel access for its oncology products[68] - The company established a Women's Health Division in early 2024 to focus on the commercialization of APL-1702 and expand its gynecological product pipeline[72] - The company is actively promoting the overseas development and collaboration opportunities for APL-1202/APL-1501 and exploring commercialization opportunities for a disposable blue-light cystoscope in the US clinic market[66] - The company is focusing on localizing production of imported drugs and devices to establish a reliable and agile supply chain while reducing costs[93] - The company is committed to providing optimal diagnostic and therapeutic solutions for bladder cancer, with a product portfolio covering NMIBC diagnosis, surgery, treatment, and follow-up[96] Environmental and Social Responsibility - The company invested 692,300 yuan in environmental protection during the reporting period[49] - The company consumed 1,921.52 tons of water and 908,100 kWh of electricity during the reporting period[51] - The company has implemented strict environmental management systems, including waste classification and hazardous waste disposal through qualified third-party companies[55][56] - The company released its first ESG report in 2023, integrating environmental, social, and governance factors into its strategic development to provide more decision-making information for investors[142] Shareholder and Employee Commitments - Employee stock ownership accounts for 4.28% of the total share capital[102] - Number of employees holding shares is 43, representing 10.91% of the total workforce[103] - Total employee shareholding is 2,437,600 shares[103] - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of listing, and will not propose the company to repurchase these shares[155] - If the company's stock price remains below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for pre-listing shares will be automatically extended by 6 months[155] - In the event of major illegal activities leading to delisting, shareholders commit not to sell their shares from the date of the administrative penalty or judicial decision until the stock is delisted[155] - Shareholders who violate the share lock-up commitments must publicly explain the reasons and apologize to shareholders and the public, with any illegal gains from share sales to be returned to the company[155] - Certain shareholders, including Pan-Scientific, have committed to a 36-month lock-up period from the listing date, with similar penalties for violations[155] - Other shareholders, such as Taizhou Donghong and Taizhou Yahong, also have a 36-month lock-up period from the listing date, with additional commitments in case of delisting due to illegal activities[157] - Some shareholders, including Nanjing Ruike and QM139, have a lock-up period of 12 months from the listing date or 36 months from the completion of the industrial and commercial registration changes, whichever is longer[157] - Directors and senior management have a 12-month lock-up period from the listing date, with additional restrictions if the company is not profitable at the time of listing[160] - If the company is not profitable at the time of listing, directors and senior management cannot sell their pre-listing shares for 3 full fiscal years, and must comply with relevant regulations even after leaving the company[160] - In case of stock price falling below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for directors and senior management will be automatically extended by 6 months[160] - The company's core technical personnel are subject to a 12-month lock-up period from the date of listing, and a 6-month lock-up period after resignation, during which they cannot transfer or entrust others to manage their shares[166] - Core technical personnel can only transfer up to 25% of their pre-IPO shares annually for 4 years after the lock-up period expires[166] - The company's directors, supervisors, and senior management are restricted from transferring more than 25% of their total shares annually after the lock-up period[163] - If the company is not profitable at the time of listing, core technical personnel cannot reduce their pre-IPO shares for 3 full fiscal years[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is not profitable at the time of listing for 3 full fiscal years[163] - The company's directors, supervisors, and senior management cannot reduce their shares within 6 months after resignation[163] - The company's core technical personnel cannot reduce their shares within 6 months after resignation[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[163] - The company's core technical personnel cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[166] - The company's directors, supervisors, and senior management must publicly explain and apologize if they violate the share reduction commitments[163] - The company plans to reduce its shareholding by no more than 100% of its total shares within two years after the lock-up period expires, with the selling price not lower than the audited net asset value per share at the end of the previous fiscal year[173] - The company will initiate stock price stabilization measures if the stock price remains below the audited net asset value per share for 20 consecutive trading days within three years of listing[172] - The company will hold a board meeting within 10 days to pass a resolution on stock repurchase and submit it to the shareholders' meeting for approval if the stock price stabilization conditions are met[172] - The company will use its own funds for stock repurchase, with the repurchase price not exceeding the latest audited net asset value per share[172] - The company will repurchase shares through centralized bidding, tender offers, or other methods approved by securities regulators, with the annual repurchase amount not exceeding 50% of the net profit attributable to the parent company's shareholders in the most recent audited fiscal year[175] - If the company's stock price remains above the audited net asset value per share for three consecutive trading days, the repurchase plan will be terminated[175] - The controlling shareholder's share purchase plan will not exceed 20% of the after-tax cash dividends received from the company in the previous year, and the purchase price will not exceed the audited net asset value per share in the most recent fiscal year[175] - Directors and senior management will purchase shares within 90 days after the controlling shareholder's plan is completed, with the purchase amount not exceeding 20% of their after-tax compensation from the company in the previous year[178] - The company will cancel repurchased shares within 10 days after the completion or termination of the repurchase plan and proceed with the capital reduction process[175] - The company will extend the period for six months after expiration and return the after-tax cash dividends received from the company in the most recent fiscal year. If not returned on time, the company may deduct from future cash dividends until the cumulative deduction reaches the total after-tax cash dividends received in the most recent fiscal year[181] - If directors or senior management fail to fulfill their commitments to stabilize stock prices within three years of listing, they must publicly explain the reasons, apologize, and propose supplementary or alternative commitments. Additionally, 20% of their monthly after-tax salary will be deducted until the cumulative deduction reaches 20% of their after-tax salary from the most recent fiscal year[181] - In case of false statements or major omissions in the prospectus that significantly affect the company's compliance with legal issuance conditions, the company will repurchase all newly issued shares. The repurchase price will be determined according to regulatory documents and will not be lower than the market price at the time of repurchase[181] - If the company violates

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688176 证券简称：亚虹医药 公告编号：2024-023 江苏亚虹医药科技股份有限公司 自愿披露关于在 2024 年第 39 届欧洲泌尿外科医学会年 会（EAU）上发布 APL-1706 用于膀胱癌诊断的临床试 验数据的公告 1、江苏亚虹医药科技股份有限公司（以下简称"公司"）APL-1706 用于膀 胱癌诊断的多中心临床试验（以下简称"本研究"）结果入选 2024 年第 39 届欧 洲泌尿外科医学会年会（EAU），并以口头汇报形式发布Ⅲ期临床试验数据。 2、目前上述产品已达到Ⅲ期临床试验主要研究终点、上市申请（NDA）已 获受理，临床试验结果能否支持药品递交上市申请、能否最终获得上市批准以及 何时获批均具有不确定性，产品获批后能否最终实现商业目的也存在一定的不确 定性。敬请广大投资者注意潜在的投资风险，公司将按有关规定及时对后续进展 情况履行信息披露义务。 一、药品基本情况 APL-1706 是目前全球唯一获批的辅助膀胱癌诊断或手术的显影剂类药 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2024-022 江苏亚虹医药科技股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2024 年 3 月，公司未通过回购专用账户以集中竞价方式回购公司股份。 截至 2024 年 3 月 31 日，公司已累计回购股份 1,325,215 股，占公司总股本的 比例为 0.2325%，回购成交的最高价为人民币 6.66 元/股，最低价为人民币 5.33 元/股，支付的资金总额为人民币 814.21 万元（ 不含印花税、交易佣金等交易费用）。 上述回购股份事项符合相关法律法规的规定及公司的回购股份方案。 三、 其他事项 重要内容提示： | 回购方案首次披露日 | 2024/2/7，由公司控股股东、实际控制人兼董事长 提议 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | 用于员工持股 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2024-021 江苏亚虹医药科技股份有限公司 关于完成公司经营范围变更的工商登记并 换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2024 年 3 月 5 日召 开第二届董事会第四次会议，于 2024 年 3 月 21 日召开 2024 年第一次临时股东 大会，分别审议通过了《关于变更公司经营范围并修订<公司章程>的议案》，同 意变更公司经营范围、修订《江苏亚虹医药科技股份有限公司章程》并办理工商 变更登记。具体内容详见公司分别于 2024 年 3 月 6 日、2024 年 3 月 22 日披露 于上海证券交易所网站（www.sse.com.cn）的《江苏亚虹医药科技股份有限公司 关于变更公司经营范围并修订<公司章程>的公告》（公告编号：2024-017）、《江 苏亚虹医药科技股份有限公司 2024 年第一次临时股东大会决议公告》（公告编 号：2024-020）。 根据公司第二届董事会第四次会议 ...

北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2024 年第一次临时股东大会的 法律意见书 务所 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 RYEUTE E- Fi A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2024 年第一次临时股东大会的法律意见书 嘉源(2024)-04-181 北京市嘉源律师事务所(以下简称"本所")接受江苏亚虹医药科技股份有 限公司(以下简称"亚虹医药"或"公司")的委托,根据《中华人民共和国公 司法》(以下简称"《公司法》")《上市公司股东大会规则》(以下简称"《股 东大会规则》")等现行有效的法律、行政法规、部门规章、规范性文件(以下 简称"法律法规")以及《江苏亚虹医药科技股份有限公司章程》(以下简称"《公 司章程》")的有关规定,指派本所律师对公司 2024年第一次临时股东大会(以 下简称"本次股东大会" ...

证券代码：688176 证券简称：亚虹医药 公告编号：2024-020 江苏亚虹医药科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 3 月 21 日 （二） 股东大会召开的地点：上海市浦东新区杨思西路 596 号上海前滩雅辰悦 居酒店 2 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 3、 董事会秘书兼财务负责人出席了本次会议。 二、 议案审议情况 （一） 非累积投票议案 | 1、出席会议的股东和代理人人数 | 32 | | --- | --- | | 普通股股东人数 | 32 | | 2、出席会议的股东所持有的表决权数量 | 207,168,272 | | 普通股股东所持有表决权数量 | 207,168,272 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 36.430 ...

证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司投资者关系活动记录表 编号：2024-009 □特定对象调研 分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 太平洋证券，西南证券，德邦证券，TPY研究院、北京泓 澄投资、北京致顺投资、财通自营、淡水泉、东海基金、 东吴基金、东吴证券、东证自营、沣杨资产、福建泽源资 产、复华投信资产、复通私募投资基金、富安达、港粤资 本、工银国际控股、广东阿米巴基金、广州创钰投资、国 华兴益保险资产、国金医药、国金证券资产管理、国君医 药、国联基金、国联证券、国泰基金、国投证券、杭州汇 ...